NCT07695701 · Phase 4 · RECRUITING
Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis
This trial tests acoramidis, a daily tablet, in people with transthyretin amyloid cardiomyopathy, a heart condition where misfolded protein builds up in the heart muscle. Scans and ultrasound will measure whether the heart's structure and function change. It is a Phase 4 trial, meaning the drug is already approved and researchers are studying its effects further.
You may qualify if
- Participants aged 18 to 80
- Confirmed diagnosis of ATTR-CM requiring targeted therapy
- At screening: New York Heart Association (NYHA) Class I/II; estimated glomerular filtration rate (eGFR) ≥40 mL/min/1.73m2; left ventricular ejection fraction (LVEF) >35%; left ventricular (LV) wall thickness ≥12 mm.
- Heart failure condition has been clinically stable for at least 6 weeks prior to screening.
You're excluded if
- Current or planned implantation of a cardiac implantable electronic device (eg, pacemaker, implantable cardiac defibrillator).
- Acute myocardial infarction, acute coronary syndrome or coronary revascularization, or experienced stroke or transient ischemic attack within 90 days prior to screening.
- Hemodynamic instability.
- Likely to undergo heart transplantation within 12 months from screening.
- Confirmed diagnosis of AL amyloidosis at screening.
- At screening: NYHA Class III/IV; National Amyloidosis Center (NAC) Stage 3.
- Prior or current treatment with acoramidis.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-07-29